Also in this playlist...
This transcript is automatically generated
-- runs a company for a medical device he claims could eventually help paralyzed people war could get interesting stuff.
Frank Reynolds is is is the CEO -- could be both therapeutics and he joins us right now.
I want to get to this real fast.
It's an implant right that's correct goes into the spinal cord supports the spinal cord -- -- doesn't deliver drugs or anything else is just to support mechanism yes that's correct all you telling me that you can help.
People walk again who would otherwise.
Never walk again.
Yes that's hard to our intention 90% of patients in arrive in the emergency room we're gonna -- with three weeks -- process it's gonna put them in a wheelchair for life.
We can mitigate that scoring process and -- -- just 10% of the spinal cord you know to spell out only 10%.
You can regain full shall recover you when you moral stance so this article is gonna go through a process chemical release presents the results it's foreign it's like of dropping a pebble in -- -- and -- ripples.
You can stop those ripples and the strength of them and we let them have less boring after that -- -- you -- implant that's correct and then those final coral locally reorganize and send signals through the spare tissue.
And allow functional recovery took -- return.
Below the point of injury.
So for -- for -- -- neck injury injured his level for breathing.
His balance sexual function should have been working the tissue was not damaged if you can't signals through that area his bowel bladder and sexual function would have function.
And that's our mission now you had trials with the monkeys -- that's correct right and Brady completed those trials that's correct you've been -- for human trials say FDAX was starting this summer that is the stage of development of this company on this particular implant that's correct the biggest challenge is really going from rats to -- not going from wants to humans so we feel we've made the biggest hurdle.
I'm no one's ever got to look at even twitch before we have them running in just three weeks all of -- -- -- that we treat run in three weeks that.
-- him -- must be very difficult to actually use human beings and you'll using them in an experimental fashion who we have the best from Harvard that's we have to have the best so well Bob one of my partner from MIT is no one medical -- of our time.
Doctors wouldn't -- and from Harvard trained neurosurgeon is the best in the business own BR -- there's two of -- the surgery -- competition.
Don't know no competition all stem cells at 1015 years through the FDA.
We have a little over a year through the FDA you know competition drives how long the human trials last -- -- -- -- we'll get a re enroll patients for about fifteen months are very quick so I'm if we see any functional recovery we think that we're gonna have a you know significant acceptance by the FDA and to get our products more competitive.
The -- it's all sound so amazing so rosy.
You know what what what are the pitfalls I mean you know whether or -- -- -- we've had no surgical complications -- side effects it's a safety study literally just a safety say the materials have been tested in rats -- monkeys we don't see any complications at all.
I'm so the -- would be maybe on.
You know some type of rare complication that we're completely unaware of believe examined every complication out -- we don't think that will be happy to searches on the bass and the richer as a well tested in humans.
-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- That region -- grows for about three weeks but we're gonna intervene early so lesion does -- crop.
And then because it doesn't -- your spare tissue around that lesion where normally -- -- Expectations are located by despondent put itself through local reorganization and signals get through and functional recovery returns right below the point of injury.
For people in wheelchairs -- -- -- stem -- -- that in the next generation of the tech knowledge of that will be putting drugs -- placement.
Chemical and feel like this treatment into the spotlight on -- -- -- -- feel the tissue and you regeneration and drug delivery and that's exactly will be doing with this technology it's a medical devices that it is a medical -- is taxed.
I get it will be a little tax -- right now don't have revenue so right now we're trying to get revenue before we worry about taxes.
How much does that -- cost I mean -- all the putting eating in the so original -- there was still working all that -- -- obviously right now the surgery that would that they're doing it doesn't work with 68000 dollars.
These patients -- gonna spend over a million dollars a first -- care.
Well over six million dollars over their life.
If you're a quadriplegic for care so the course of this is enormously just paint a rosy picture then I mean you like gee whiz technology and we really want what -- -- and our preclinical data all do of course we do.
But we do preclinical data rats monkeys we have wonderful success and all that we've published -- one global awards.
We've presented in Stockholm you know a lot of people are aware of this technology FDA's give us a green light.
We've put the right team together and we have the number one medically manner in history on our -- so we publicly traded company that's correct our -- -- was and the ID.
And we're just not think I have to ask you what's your ownership of -- -- actually yeah the company you go on about 15 of the company I'm very proud that we watch every single penny I was tell people that I'm you know about a 24% of every dollar we spend as months we're gonna watch it.
All right well look we wish you the very best of luck real success obviously -- -- a very interesting product thank you very much -- -- thank you.
Filter by section